Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

In this video, Robert DeBernardo, MD, shares insight on antibody-drug conjugates as treatment for patients with cancer, a topic discussed at Society of Gynecologic Oncology Annual Meeting on Women’s ...

CSPC PHARMA (01093.HK) announced that the Investigational New Drug (IND) application for SYS6041 (Antibody-Drug Conjugate) ...

Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the ...

A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in ...

No writing assistance was utilized in the production of this manuscript. Several antibody–drug conjugates (ADCs), using different combinations of antibody, cytotoxic agents and linkers ...

Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...

Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ ...

“The initiation of the Phase 1 clinical trial being conducted by our development partner CSPC Pharmaceutical Group in China is a significant milestone for Radiance and RB-164™ (SYS6005),” said Robert ...

BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs ...